2025-524741-28-00Not yet recruitingPhase 4
BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Jun 2026
Brief summary (registry, in English)
To evaluate the feasibility and safety of gradual interval prolonging of biologics during ~1 year in patients with severe asthma
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 142 (estimated)
- First submitted
- 19 Feb 2026
- Start date
- 1 Mar 2026
- Lead sponsor
- Amsterdam UMC Stichting
- Diseases
- Asthma
- EU CT number
- 2025-524741-28-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 142
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other
- Uncontrolled asthma (>1 exacerbation in the past 12 months or ACQ > 2.0)
- Pregnancy
- Intention to become pregnant within the next 12 months
- Biologic administration intervals already prolonged beyond the approved regimen according to the SmPC at the patient’s request
- Inability to understand and communicate in Dutch or English, both spoken and written
Who the study is looking for
- Receiving biological treatment (mepolizumab, reslizumab, benralizumab, dupilumab, or tezepelumab) for more than 12 months
- ≥18 years of age
- 0 or 1 exacerbation in the past 12 months
- Baseline ACQ < 2.0
- Blood eosinophil count ≤0.3 +10^9/L for anti-IL-5(R)/Tezepelumab, ≤1.5 +10^9/L for Dupilumab
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC Stichting | Amsterdam | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.